Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials

The cardiovascular safety from azithromycin in the treatment of several infectious diseases has been challenged. In this prespecified pooled analysis of 2 multicenter randomized clinical trials, we aimed to assess whether the use of azithromycin might lead to corrected QT (QTc) interval prolongation or clinically relevant ventricular arrhythmias. In the COALITION COVID Brazil I trial, 667 patients admitted with moderate COVID-19 were randomly allocated to hydroxychloroquine, hydroxychloroquine plus azithromycin, or standard of care.

Source: The American Journal of Cardiology - January 18, 2024 Category: Cardiology Authors: Remo H.M. Furtado, Pedro G.M. Barros e Silva, Henrique A.R. Fonseca, Ary Serpa-Neto, Thiago D. Correa, H élio P. Guimarães, Adriano J. Pereira, Guilherme B. Olivato, Fernando G. Zampieri, Thiago Lisboa, Debora L.M. Junqueira, Maura G. Lapa, Frederico Mo Source Type: research